Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KLRSOTCMKTS:NVLNFNASDAQ:PEPGOTCMKTS:TRUU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKLRSKalaris Therapeutics$2.50-2.3%$0.00$2.28▼$24.15$46.75M0.4837,450 shs35,701 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsPEPGPepGen$1.22+0.8%$1.44$0.88▼$19.30$39.92M1.16844,504 shs152,259 shsTRUUTrue Drinks$0.10-5.1%$0.10$0.00▼$0.08$493.19M10.91.01 million shs15,021 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKLRSKalaris Therapeutics0.00%-4.58%-24.24%+249,999,900.00%+249,999,900.00%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%PEPGPepGen0.00%+6.09%-18.67%+10.91%-92.76%TRUUTrue Drinks0.00%-0.32%-5.90%+98.36%-41.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APEPGPepGen2.9401 of 5 stars3.23.00.00.01.82.51.3TRUUTrue DrinksN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKLRSKalaris Therapeutics 0.00N/AN/AN/ANVLNFNovelion Therapeutics 0.00N/AN/AN/APEPGPepGen 2.33Hold$7.67528.42% UpsideTRUUTrue Drinks 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NVLNF, TRUU, PEPG, and KLRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/9/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKLRSKalaris TherapeuticsN/AN/AN/AN/A$22.47 per shareN/ANVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15PEPGPepGenN/AN/AN/AN/A$3.64 per shareN/ATRUUTrue Drinks$1.95M252.92N/AN/A($0.03) per share-3.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKLRSKalaris Therapeutics-$58.77MN/A0.00∞N/AN/A-62.08%-54.69%N/ANVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/APEPGPepGen-$89.98M-$3.13N/AN/AN/AN/A-81.26%-63.65%8/6/2025 (Estimated)TRUUTrue Drinks-$3.88M$0.019.92∞N/A-255.80%N/A-165.86%N/ALatest NVLNF, TRUU, PEPG, and KLRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PEPGPepGen-$0.72-$0.92-$0.20-$0.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ATRUUTrue DrinksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKLRSKalaris TherapeuticsN/A14.3114.31NVLNFNovelion TherapeuticsN/AN/AN/APEPGPepGenN/A4.954.95TRUUTrue DrinksN/A0.01N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKLRSKalaris Therapeutics66.05%NVLNFNovelion Therapeutics48.64%PEPGPepGen58.01%TRUUTrue DrinksN/AInsider OwnershipCompanyInsider OwnershipKLRSKalaris Therapeutics74.99%NVLNFNovelion Therapeutics3.60%PEPGPepGen4.60%TRUUTrue Drinks18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKLRSKalaris Therapeutics11018.70 million4.68 millionN/ANVLNFNovelion Therapeutics10919.62 millionN/ANot OptionablePEPGPepGen3032.72 million31.22 millionNot OptionableTRUUTrue Drinks404.97 billionN/ANot OptionableNVLNF, TRUU, PEPG, and KLRS HeadlinesRecent News About These CompaniesTrue Drinks (OTCMKTS:TRUU) Shares Cross Below Fifty Day Moving Average - Here's WhyJune 26, 2025 | marketbeat.comBeer News: True Acts Of Aletruism / New “Indie Beer” CampaignNovember 13, 2024 | americancraftbeer.comAHow Much Alcohol Can You Drink a Week and Still Be Healthy?November 13, 2024 | msn.comStarbucks holiday menu: What's the healthiest drink? How much sugar, caffeine is in the seasonal beverages and other nutritional factsNovember 9, 2024 | msn.comCan You Drink Alcohol After Getting a COVID-19 Booster?October 29, 2024 | health.comHIt's True: Some Pizza Hut Locations Still Serve AlcoholOctober 22, 2024 | yahoo.comReview: True Story Finished BourbonOctober 21, 2024 | msn.comVitalizes Body and Mind.®October 4, 2024 | redbull.comR7UP confirms limited release of ‘most overdue’ soda flavor: ‘Dream come true’October 2, 2024 | msn.com‘Diabetes in a cup!’ Dunkin worker reveals most ‘absurd’ drink he’s ever made — here’s what’s in itSeptember 21, 2024 | nypost.comNSeattle’s True Loves Drop a Funky New SingleAugust 31, 2024 | msn.comCannabis Beverage of the Week: Nowadays stands out in a crowded field of THC drinksAugust 31, 2024 | msn.comThese alcoholic drinks can raise the risk of gout, a painful type of arthritisAugust 30, 2024 | nypost.comN14 Drinks You Should Think Twice About Ordering At A Bar, According To A Master MixologistAugust 29, 2024 | yahoo.com7 things you NEED to know about Prime Drinks (and the very different things the internet will tell you)August 25, 2024 | bbc.co.uk12 Unhealthiest Drinks You Should Think Twice About Ordering At A BarAugust 18, 2024 | msn.comTrue Loaf Bakery gets starter from two local bakersAugust 10, 2024 | msn.comPD TRUE : STREAM IT OR SKIP IT?August 6, 2024 | decider.comD10 Drinks People Fake Liking to Fit InAugust 5, 2024 | msn.com16 Best Summer Cocktails for a Hot Weather BuzzJuly 26, 2024 | esquire.comEWhat is ‘fluffy Coke’? Sugary drink dubbed ‘diabetes in a cup’ is the hottest beverage of the summerJuly 23, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVLNF, TRUU, PEPG, and KLRS Company DescriptionsKalaris Therapeutics NASDAQ:KLRS$2.50 -0.06 (-2.34%) As of 07/3/2025 01:00 PM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Novelion Therapeutics OTCMKTS:NVLNF$0.70 -0.01 (-1.20%) As of 01/16/2020Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.PepGen NASDAQ:PEPG$1.22 +0.01 (+0.83%) Closing price 07/3/2025 02:21 PM EasternExtended Trading$1.24 +0.02 (+1.64%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.True Drinks OTCMKTS:TRUU$0.10 -0.01 (-5.07%) As of 07/3/2025True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
